Zachary S Wallace1,2,3,4, Xiaoqing Fu1,2,3, Tyler Harkness1,2,3, John H Stone2,3,4, Yuqing Zhang1,2,3,4, Hyon Choi2,3,4. 1. Clinical Epidemiology Program, Mongan Institute. 2. Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, all at. 3. Massachusetts General Hospital. 4. Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: The objective of this study was to evaluate causes of death in a contemporary inception cohort of ANCA-associated vasculitis patients, stratifying the analysis according to ANCA type. METHODS: We identified a consecutive inception cohort of patients newly diagnosed with ANCA-associated vasculitis from 2002 to 2017 in the Partners HealthCare System and determined vital status through the National Death Index. We determined cumulative mortality incidence and standardized mortality ratios (SMRs) compared with the general population. We compared MPO- and PR3-ANCA+ cases using Cox regression models. RESULTS: The cohort included 484 patients with a mean diagnosis age of 58 years; 40% were male, 65% were MPO-ANCA+, and 65% had renal involvement. During 3385 person-years (PY) of follow-up, 130 patients died, yielding a mortality rate of 38.4/1000 PY and a SMR of 2.3 (95% CI: 1.9, 2.8). The most common causes of death were cardiovascular disease (CVD; cumulative incidence 7.1%), malignancy (5.9%) and infection (4.1%). The SMR for infection was greatest for both MPO- and PR3-ANCA+ patients (16.4 and 6.5). MPO-ANCA+ patients had an elevated SMR for CVD (3.0), respiratory disease (2.4) and renal disease (4.5). PR3- and MPO-ANCA+ patients had an elevated SMR for malignancy (3.7 and 2.7). Compared with PR3-ANCA+ patients, MPO-ANCA+ patients had a higher risk of CVD death [hazard ratio 5.0 (95% CI: 1.2, 21.2]; P = 0.03]. CONCLUSION: Premature ANCA-associated vasculitis mortality is explained by CVD, infection, malignancy, and renal death. CVD is the most common cause of death, but the largest excess mortality risk in PR3- and MPO-ANCA+ patients is associated with infection. MPO-ANCA+ patients are at higher risk of CVD death than PR3-ANCA+ patients.
OBJECTIVE: The objective of this study was to evaluate causes of death in a contemporary inception cohort of ANCA-associated vasculitispatients, stratifying the analysis according to ANCA type. METHODS: We identified a consecutive inception cohort of patients newly diagnosed with ANCA-associated vasculitis from 2002 to 2017 in the Partners HealthCare System and determined vital status through the National Death Index. We determined cumulative mortality incidence and standardized mortality ratios (SMRs) compared with the general population. We compared MPO- and PR3-ANCA+ cases using Cox regression models. RESULTS: The cohort included 484 patients with a mean diagnosis age of 58 years; 40% were male, 65% were MPO-ANCA+, and 65% had renal involvement. During 3385 person-years (PY) of follow-up, 130 patients died, yielding a mortality rate of 38.4/1000 PY and a SMR of 2.3 (95% CI: 1.9, 2.8). The most common causes of death were cardiovascular disease (CVD; cumulative incidence 7.1%), malignancy (5.9%) and infection (4.1%). The SMR for infection was greatest for both MPO- and PR3-ANCA+ patients (16.4 and 6.5). MPO-ANCA+ patients had an elevated SMR for CVD (3.0), respiratory disease (2.4) and renal disease (4.5). PR3- and MPO-ANCA+ patients had an elevated SMR for malignancy (3.7 and 2.7). Compared with PR3-ANCA+ patients, MPO-ANCA+ patients had a higher risk of CVDdeath [hazard ratio 5.0 (95% CI: 1.2, 21.2]; P = 0.03]. CONCLUSION: Premature ANCA-associated vasculitis mortality is explained by CVD, infection, malignancy, and renal death. CVD is the most common cause of death, but the largest excess mortality risk in PR3- and MPO-ANCA+ patients is associated with infection. MPO-ANCA+ patients are at higher risk of CVDdeath than PR3-ANCA+ patients.
Authors: John Cologne; Wan-Ling Hsu; Robert D Abbott; Waka Ohishi; Eric J Grant; Saeko Fujiwara; Harry M Cullings Journal: Epidemiology Date: 2012-07 Impact factor: 4.822
Authors: Ju Ann Tan; Natasha Dehghan; Wenjia Chen; Hui Xie; John M Esdaile; J Antonio Avina-Zubieta Journal: Ann Rheum Dis Date: 2017-05-03 Impact factor: 19.103
Authors: Eleana Ntatsaki; David Carruthers; Kuntal Chakravarty; David D'Cruz; Lorraine Harper; David Jayne; Raashid Luqmani; John Mills; Janice Mooney; Michael Venning; Richard A Watts Journal: Rheumatology (Oxford) Date: 2014-04-11 Impact factor: 7.580
Authors: Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: Julia U Holle; Wolfgang L Gross; Ute Latza; Bernhard Nölle; Petra Ambrosch; Martin Heller; Regina Fertmann; Eva Reinhold-Keller Journal: Arthritis Rheum Date: 2011-01
Authors: Aladdin J Mohammad; Lennart T H Jacobsson; Kerstin W A Westman; Gunnar Sturfelt; Mårten Segelmark Journal: Rheumatology (Oxford) Date: 2009-10-01 Impact factor: 7.580
Authors: Giorgio Trivioli; Ana Marquez; Davide Martorana; Michelangelo Tesi; Andreas Kronbichler; Paul A Lyons; Augusto Vaglio Journal: Nat Rev Rheumatol Date: 2022-09-15 Impact factor: 32.286
Authors: Pil Gyu Park; Jung Yoon Pyo; Sung Soo Ahn; Hyun Joon Choi; Jason Jungsik Song; Yong-Beom Park; Ji Hye Huh; Sang-Won Lee Journal: Front Cardiovasc Med Date: 2022-06-23
Authors: Hyeok Chan Kwon; Jung Yoon Pyo; Lucy Eunju Lee; Sung Soo Ahn; Jason Jungsik Song; Yong Beom Park; Sang Won Lee Journal: J Korean Med Sci Date: 2021-05-10 Impact factor: 2.153